A Phase I Study of BIIB015, a Humanized, IgG1, DM4-Conjugated, Anti-Cripto, Monoclonal Antibody, for the Treatment of Subjects With Relapsed or Refractory Solid Tumors

Inclusion Criteria

Inclusion Criteria

- Age 18 years or older at the time of informed consent.

- Solid tumors that are relapsed or refractory to at least 1 prior anti-cancer systemic
therapy and for which no standard therapy exists.

- ECOG Performance Status
Exclusion Criteria

- History of keratoconjunctivitis, open or closed angle glaucoma, or "dry eye" disease.

- New York Heart Association (NYHA) Grade II or greater congestive heart failure.

- History of myocardial infarction within 6 months prior to Day 1.

- Presence of >/= Grade 2 peripheral neuropathy.

- Known presence of central nervous system or brain metastases.

- Prior therapy with a conjugated or unconjugated maytansine derivative.